Kevin Koch

President and CEO

2017

Discovering and developing novel therapies for the treatment of life threatening musculoskeletal disease.

Venture Partner

2016

Senior Vice President, Drug Discovery, Chemical & Molecular Therapeutics

2013 - 2015

Oversight of drug discovery efforts at the company including protein therapeutics and small molecule discovery platforms, the immunology and hematology therapeutic areas, global biomarker discovery and development, external drug discovery collaborations and technology groups to enhance the rate and quality of the drug discovery process including structural biology, HTS, phenotypic screening and chemical proteomics. Chair of Discovery Leadership Governance Team, member of the Sr. Research and Development management team and associated oversight committees for Biogen R&D governance. Evaluation of Business Development Opportunities. Oversight of ~320 R&D professionals.

President and Chief Scientific Officer, Company Founder

1998 - 2013

Fully integrated, structure based design driven, pharmaceutical company discovering and developing small molecule drugs for the treatment cancer, diabetes, pain, respiratory and autoimmune disease. Oversight of all internal and external research as well as early development including translational medicine and clinical pharmacology teams. Array scientists are inventors of 21 compounds that have moved into clinical development via internal and external Array programs. 15 compounds remain in development with 10 in Ph2 studies and 3 molecule sin Phase 3. Member Development Strategy Committee, Chair Research Milestone Group. Member of Joint Research and Development committees for most Array collaborations. Business development. Scientific liaison for all investor interactions including fund-raising for over $500M in public financing and quarterly conference calls. Co-inventor on 4 Array development compounds. Member Board of Directors May, 1998 - November 2012.

President and Chief Scientific Officer

2000 - 2007

Lead research and early development. Built enzymology, high-throughput screening, drug metabolism, pharmacology, toxicology, clinical pharmacology, regulatory, clinical operations and translational medicine teams. Managed external KOL interactions to design clinical trials for Array POC studies. Built chemical process research and development team including GMP manufacture, formulation, drug product QA and QC. Direct budgetary oversight of > 250 R&D professionals. Moved 8 Array internal discovery programs into Ph1/2 clinical studies.

Co-Founder Array BioPharma

1998 - 2000

Co-Founder Array BioPharma. Developed business plan providing a small molecule discovery platform (combinatorial chemistry, medicinal chemistry, protein crystallography, computational chemistry, cell biology) to genomics and pharmaceutical companies growing company from 25 original FTE to ~125 FTE. Drove development of first integrated electronic data capture platform for research in industry. Defined scientific ladder, performance evaluation, organizational structure and strategic goals to optimize the discovery research culture to achieve high productivity. Scientific lead on all Business development interaction. Scientific and strategic lead in public offering 11/2000.

Associate Director, Medicinal Chemistry

1995 - 1998

Protease Inhibitor and New Technologies group

Senior Research Investigator

1993 - 1995

Project Coordinator: Immunology and Cell Adhesion

Inventor

1988 - 1995

Inventor two LTB4 antagonists evaluated in Ph1/2 studies Development candidate nomination for transplantation

Senior Research Scientist

1991 - 1993

Project Coordinator: Immunology

Research Scientist

1988 - 1991

Associate Scientist, Process Research

1983 - 1984